Progressive Multifocal Leukoencephalopathy: Opportunistic Infection in ART Era

Amit Vahia  
*Henry Ford Health System*

Indira Brar  
*Henry Ford Health System*

Follow this and additional works at: [https://scholarlycommons.henryford.com/merf2019caserpt](https://scholarlycommons.henryford.com/merf2019caserpt)

Recommended Citation

This Poster is brought to you for free and open access by the Medical Education Research Forum 2019 at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Case Reports by an authorized administrator of Henry Ford Health System Scholarly Commons. For more information, please contact acabrer4@hfhs.org.
PML: Still Relevant in the ART Era  
Amit Vahia MD MPH and Indira Brar MD  
Division of Infectious Diseases  
Henry Ford Health System, Detroit, Michigan

Progressive Multifocal Leukoencephalopathy is a rare, often fatal demyelinating neurological disease seen in profoundly immunocompromised patients. It is caused by reactivation of JC Virus.

The diagnosis is made by CSF PCR for Polyomavirus JC. The test is 72-92% sensitive and 92-100% specific for the disease. Treatment is aimed toward correcting the patient’s underlying immunodeficiency.

MRI Brain: Demonstrates a large lesion in the left cerebellar hemisphere. The lesion demonstrates low signal intensity on T1, high signal intensity on T2/FLAIR, without diffusion restriction or enhancement. Companion lesions in the right parietal and left frontal lobes have predilection for the cerebral cortex white matter.

Introduction

PML is a demyelinating disease caused by reactivation of the polyomavirus JC. Asymptomatically acquired in childhood with positive antibodies in 86% adults. Lies dormant in the kidney and lymphoid tissue. With profound IS, reactivation occurs with spread to CNS and demyelinating disease of oligodendrocytes. Since the widespread use of combined ART, the incidence of PML in patients with HIV infection has decreased. In a population-based study from Denmark involving a nationwide cohort of patients aged 16 and older with HIV infection, the incidence of PML declined from 3.3 cases/1000 patient years at risk to 1.1 cases/1000 patient years at risk.

History of Present Illness

A 33 year old gentleman presented to Henry Ford Hospital in November 2018 with lower extremity weakness, fatigue, and progressive difficulty with activities of daily living over the last 2-3 weeks with multiple falls at home. Associated with 20 lb. weight loss over the same period. Denied any other infectious symptoms of fever, chills, nausea, vomiting, diarrhea, rash, joint pain, URI symptoms, dysuria, genital lesions or other problems. He denied sick contacts or recent travel or occupational exposure. Admitted to sexual promiscuity with high risk female partners in years past.

Physical Examination

• BP 129/93, RR 18, Pulse 77, Temp 36.7  
• BMI 17.9  
• Diminished muscle bulk  
• Dysdiadokokinesia and dysmetria on right hand  
• Preserved mental status  
• Slowed speech and movement.

Lab Findings

• HIV positive 4th generation testing.  
• CD4 count 35  
• HIV Viral load 500,000  
• CSF JC Virus PCR: Positive

Types of PML

Classical  
• Variable neurological deficits patient to patient. Ataxia, hemianopia, weakness  
• T cell count less than 200

Inflammatory  
• Paradoxical unmasking of PML due to IRIS  
• Better prognosis than classical

JC virus cerebellar granule cell neuronopathy  
• Ataxia and cerebellar atrophy  
• Mutations in the structure of the JC virus VP1 capsid

JC virus meningitis: More typical headache, photophobia, nuchal rigidity presentation.

JC virus encephalopathy: Rarely described, but rapidly fatal

Treatment

• Correct the underlying immunodeficiency by starting ART in AIDS patients.  
• Remove offending drugs for those patients exposed to notorious immunomodulator therapies like natalizumab in Multiple Sclerosis.  
• Plasma exchange and steroids have been used to varied but unreliable success.  
• Investigational therapies including cytarabine, cidofovir, topotecan, mirtazapine, mefloquine, maraviroc have been tried unsuccessfully.  
• Outcome is often fatal and if not, leaves patients with significant neurological deficits. Our patient succumbed to his illness 1 month after presentation.

References:  
1) Weber et al, CID 1997  
2) Cinque P, AIDS 1997  
3) Marzocchetti A, J Clinical Microbio 2005